Journal of Applied Physiology AJP: Endocrinology and Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Appl Physiol 100: 1019-1026, 2006. First published November 10, 2005; doi:10.1152/japplphysiol.00388.2005
8750-7587/06 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
100/3/1019    most recent
00388.2005v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Behnke, B. J.
Right arrow Articles by Poole, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Behnke, B. J.
Right arrow Articles by Poole, D. C.

Effects of arterial hypotension on microvascular oxygen exchange in contracting skeletal muscle

Brad J. Behnke,1,2 Danielle J. Padilla,1 Leonardo F. Ferreira,1 Michael D. Delp,2 Timothy I. Musch,1 and David C. Poole1

1Department of Kinesiology and the Clarenburg Laboratory in the Department of Anatomy and Physiology, Kansas State University, Manhattan, Kansas; and 2Division of Exercise Physiology, West Virginia University School of Medicine, Morgantown, West Virginia

Submitted 5 April 2005 ; accepted in final form 7 November 2005


    ABSTRACT
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
In healthy animals under normotensive conditions (N), contracting skeletal muscle perfusion is regulated to maintain microvascular O2 pressures (PmvFormula) at levels commensurate with O2 demands. Hypovolemic hypotension (H) impairs muscle contractile function; we tested whether this condition would alter the matching of O2 delivery (QO2) to O2 utilization (VO2), as determined by PmvFormula at the onset ofmuscle contractions. PmvFormula in the spinotrapezius muscles of seven female Sprague-Dawley rats (280 ± 6 g) was measured every 2 s across the transition from rest to 1-Hz twitch contractions. Measurements were made under N (mean arterial pressure, 97 ± 4 mmHg) and H (induced by arterial section; mean arterial pressure, 58 ± 3 mmHg, P < 0.05) conditions; PmvFormula profiles were modeled using a multicomponent exponential fitted with independent time delays. Hypotension reduced muscle blood flow at rest (24 ± 8 vs. 6 ± 1 ml–1·min–1·100 g–1 for N and H, respectively; P < 0.05) and during contractions (74 ± 20 vs. 22 ± 4 ml–1·min–1·100 g–1 for N and H, respectively; P < 0.05). H significantly decreased resting PmvFormula and steady-state contracting PmvFormula(19.4 ± 2.4 vs. 8.7 ± 1.6 Torr for N and H, respectively, P < 0.05). At the onset of contractions, H reduced the time delay (11.8 ± 1.7 vs. 5.9 ± 0.9 s for N andH, respectively, P < 0.05) before the fall in PmvFormula and accelerated therate of PmvFormula decrease (time constant, 12.6 ± 1.4 vs. 7.3 ± 0.9 s for N and H, respectively, P < 0.05). Muscle VO2 was reduced by 71% at rest and 64% with contractions in H vs. N, and O2 extraction during H averaged 78% at rest and 94% during contractions vs. 51 and 78% in N. These results demonstrate that H constrains the increase of skeletal muscle QO2 relative to that of VO2 at the onset of contractions,leading to a decreased PmvFormula. According to Fick's law, this scenario will decrease blood-myocyte O2 flux, thereby slowing VO2 kinetics and exacerbating the O2 deficit generated at exercise onset.

oxygen delivery; oxygen utilization; rat spinotrapezius muscle; exercise; kinetics


IN THE MUSCLES OF HEALTHY individuals, blood flow (Q) and therefore oxygen delivery (QO2) increases rapidly at the onset of exercise. The QO2 dynamics are so rapid that they either match or exceed the rate of O2 utilization (VO2) such that the microvascular pressure of O2 (PmvFormula) and the venous O2 content are either unchanged or may even increase above resting values for 10–15 s before they decrease exponentiallytoward lower steady-state values (3, 4, 19). Because PmvFormula represents the driving force for blood-muscle O2 movement, it is crucial to maintain PmvFormula as high as possible both across the rest-exercise transition and during the subsequent steady state.

In disease states such as diabetes (6) and chronic heart failure (CHF) (15), there is a mismatch of QO2 and VO2 dynamics such that PmvFormula falls below values found in healthy muscles. Considering that VO2 = DO2 x (PmvFormula– mitochondrial PO2), where DO2 is the effective muscle O2 diffusing capacity, the reduced PmvFormula contributes to the slowed VO2 kinetics typical of these conditions (23, 49, 61). The ability to increase muscle QO2 rapidly at the onset of contractions is dependent on the ability to increase the product of the pressure differential across the muscle ({Delta}P) and vascular conductance within the muscle vascular bed (i.e., {Delta}Q = {Delta}P x {Delta}vascular conductance). Impairment of either factor would be expected to compromise QO2 unless there was a reciprocal change in its counterpart.

Numerous conditions exist that lead to profound systemic hypotension. These include physiological conditions, such as prolonged exercise leading to dehydration (12), bed rest (22), and microgravity during space flight (14), as well as pathological conditions, such as autonomic dysfunction (29, 58, 72), chronic fatigue syndrome (CFS) (48, 62), fibromyalgia (63), and cardiovascular diseases [e.g., mitral valve prolapse syndrome (9, 28), congestive heart failure (during exercise, Ref. 38), atrial fibrillation (1), hyponatremic CHF patients treated with captopril (45)]. In addition, a significant minority of otherwise healthy people experience occasional or frequent attacks of presyncope or syncope (41). All of these conditions are associated with fatigue and exercise intolerance, and it is probable that the associated hypotension impairs exercising muscle QO2 and disrupts blood-muscle O2 transfer, in part, due to the reduced PmvFormula.

The purpose of the present investigation was to determine the effects of systemic hypovolemic hypotension induced by arteriosection (i.e., withdrawal of blood from the carotid artery) on the dynamic matching of QO2 and VO2 at the onset of muscle contractions as assessed from the profile of PmvFormula as well as that of muscle blood flow and O2 uptake. We hypothesized that relative to the normotensive condition, hypotension would impair QO2 at the onset of contractions such that PmvFormula would fall more rapidly and be reduced below its normotensive value across the rest-contractions transition and in the subsequent steady state.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Six-month-old female Sprague-Dawley rats (280 ± 6 g, n = 14) were housed individually at 23°C and were maintained on a 12:12-h light-dark cycle. All rats were fed rat chow and water ad libitum. All procedures were approved by the Institutional Animal Care and Use Committee at Kansas State University.

Surgical preparation for PmvFormula measurements.   Rats were anesthetized with pentobarbital sodium (40 mg/kg ip, to effect). The carotid artery was cannulated using PE-50 tubing (Intra-Medic polyethylene tubing; Clay Adams, Sparks, MD). This provided a route of access for infusion of the phosphorescent probe at 15 mg/kg, monitoring of arterial blood pressure (Digi-Med BPA model 200, Louisville, KY), blood sampling, and blood withdrawal for induction of hypotension. Blood withdrawal for blood PO2 determination (Nova Stat Profile M, Waltham, MA), and hematocrit (Adams Micro-Hematocrit reader, Clay Adams, Parsipanny, NJ) was performed immediately after the stimulation periods. The left spinotrapezius was exposed as described previously (2, 15). Briefly, the skin and overlying fascia not intimately connected to the myocytes were removed carefully from the dorsal aspect of the muscle. Vascular and neural tissues that branch primarily from the scapular origin of the spinotrapezius were left undisturbed. Stainless steel electrodes were used to stimulate the muscle. The cathode was placed in close proximity to the motor point (0.5–1.0 cm caudal to the scapula), whereas the anode was sutured in place at the caudal edge of the muscle, near the fourth thoracic vertebra. Stimulation conditions (i.e., voltage and placement of electrodes) were maintained constant between stimulation periods (i.e., for normotensive and hypotensive conditions). The phosphor palladium meso-tetra-(4-carboxyphenyl)-porphyrin dendrimer (R2; Oxygen Enterprises, Philadelphia, PA) was infused at a dose of 15 mg/kg through the arterial cannula ~15 min before each experiment.

The muscle was kept moist throughout the experiment using a Krebs-Henseleit bicarbonate-buffered solution equilibrated with 5% CO2/95% N2 at 38°C. The muscle was stimulated to contract at 1 Hz (~4–6 V, 2.0-ms pulse duration, twitch contractions) for 4 min with a Grass S88 stimulator. After completion of the control stimulation period, ~5 ml of blood (4.8 ± 0.3 ml) was withdrawn to induce a fall in mean arterial pressure (MAP) of ~40 mmHg, and the rats were then allowed to stabilize for 30 min. This provided a rest period of at least 45 min between stimulation bouts to preclude "priming" effectson the muscle PmvFormula response (7). After the stabilization period, the muscle was stimulated for a second bout (parameters held constant),and PmvFormula was measured over the same portion of the muscle asduring the first protocol. PmvFormula measurements were recorded every 2 s throughout rest and both stimulation periods.

After completion of the experiment, each rat was euthanized with an overdose of anesthesia (pentobarbital sodium, 50 mg/kg ia).

PmvFormula measurements and calculations.   A PMOD 1000 frequency domain phosphorimeter probe (Oxygen Enterprises, Philadelphia, PA) was positioned ~2 mm above the spinotrapezius, as described by Bailey et al. (2). A light guide contained within the probe focuses excitation light (524 nm) on the medial region of the exposed spinotrapezius (~2.0-mm diameter, to ~500 µm deep). The PMOD 1000 uses a sinusoidal modulation of the excitation light at frequencies between 100 Hz and 20 kHz, which allows phosphorescence lifetime measurements from 10 µs to ~2.5 ms. In the single frequency mode, 10 scans (10 ms/scan for 100 ms total) were used to acquire the resultant lifetime of the phosphorescence (700 nm) and repeated every 2 s (for review, see Ref. 66). The phosphorescence lifetime was obtained computationally based on the decomposition of data vectors to a linearly independent set of exponentials (67).

The Stern-Volmer relationship allows the calculation of PmvFormula from a measured phosphorescence lifetime using the following equation (57):

Formula 1(1)
where kQ is the quenching constant (mmHg/s) and t° and t are the phosphorescence lifetimes in the absence of O2 and at the ambient O2 pressure, respectively. For R2, with in vitro conditions similar to those found in the blood, kQ is 409 mmHg/s and t° is 601 µs (36). R2 is tightly bound to albumin in the plasma and is negatively charged. These properties, in combination with the extremely high albumin reflection coefficients in skeletal muscle (for review, see Ref. 50), ensure that the PO2 measurements emanate from the plasma within the microvasculature rather than the surrounding muscle tissue (47). Unlike near infrared spectroscopy, the PmvFormula 1 signal is not subject to contamination from intramyocyte myoglobin. Moreover, PmvFormula 1 represents the O2 pressure head for diffusive blood-myocyte O2 movement. The phosphorescence lifetime is insensitive to probe concentration, excitation light intensity, and absorbance by other chromophores in the tissue (57). The effects of pH and temperature are negligible within the normal physiological range, which was maintained herein (36, 46). In addition, as most of the O2 off-loading occurs on the linear portion of the O2 dissociation curve and all PmvFormula 1 measurements are on that linear portion, it follows that PmvFormula 1 is proportional to Formula 1O2/Formula 1O2. There will, of course, be some uncertainties related to the precise position of the O2 dissociation curve and changes thereof along the intramuscular vascular tree.

Blood flow measurements.   Blood flow was determined in a second set of seven animals using the radionuclide-tagged microsphere technique (42). Initially, rats were anesthetized with pentobarbital sodium (40 mg/kg ip, to effect). Polyethlene catheters (PE-10 connected to PE-50) were emplaced in the right carotid and caudal (tail) arteries. The carotid artery catheter was advanced 2–3 mm rostral to the aortic valve and secured. The tail artery catheter was advanced toward the bifurcation of the descending aorta and secured. The carotid artery catheter was connected to a pressure transducer. Arterial blood pressure and heart rate were measured (Digi-Med BPA model 200). The tail artery catheter was connected to a 5-ml glass syringe, which was attached to a Harvard withdrawal pump (model 907, Cambridge, MA).

Blood flow was measured in the right (resting) and left (contracting) spinotrapezius muscles during normotensive and hypotensive conditions. Both spinotrapezius muscles were surgically exposed, with electrodes being placed on the left muscle. Microspheres were infused after 3 min of left spinotrapezius contractions for each condition with the right, quiescent spinotrapezius serving as the control (i.e., resting) condition. After the first microsphere was infused, hypotension was induced identically as that employed for phosphorescent quenching measurements (i.e., arteriosection of ~5 ml blood), and the muscle and animal allowed ~30 min to stabilize before the second microsphere label was infused. Two different microspheres (46Sc, 85Sr) with a diameter of 15 µm (New England Nuclear, Boston, MA) were infused in random order. Before infusion, the microspheres were agitated by sonication to suspend the beads and prevent clumping. Thirty seconds before infusion was initiated, blood withdrawal from the caudal artery at 0.25 ml/min was begun. The right carotid artery catheter was disconnected from the pressure transducer, and a specified microsphere (~2.5 x 105 in number) was infused into the ascending aorta and flushed with saline to ensure clearance of the beads. Blood withdrawal from the caudal artery continued for 45 s after microsphere infusion.

After the final microsphere infusion, the rats were killed with an overdose of pentobarbital sodium (>80 mg/kg) via the right carotid artery catheter. After correct placement of the carotid catheter was verified, the left and right spinotrapezius and kidneys were removed. The radioactivity levels of the tissues were determined by a two-channel gamma scintillation counter (Packard Auto Gamma spectrometer, model 5230) set to record the peak energy activity of each isotope for 5 min. Total blood flow to each tissue was calculated by the reference sample method (27, 42) and expressed in milliliters per minute per 100 g of tissue. Adequate mixing of the microspheres was verified by demonstrating a <15% difference in blood flows to the right and left kidneys.

Calculated O2 uptake.   Resting and steady-state contracting muscle Formula 1O2 (Formula 1O2m) were estimated using the Fick equation assuming that PmvFormula 1 is an appropriate analog for venous PO2 (40, 54). Formula 1O2m was estimated using arterial blood gases, hemoglobin content, PmvFormula 1, and measured blood flow and reported (in ml O2·min–1·100 g of tissue–1). Considering that no change was observed in muscle temperature or blood pH and the relatively light workload performed by the muscle, no appreciable shift in the O2 dissociation curve would be expected.

Statistical analysis.   KaleidaGraph software (Kaleidagraph 3.5) was used to describe the time course of each PmvFormula 1 response using an exponential function, following a time delay (TD):

Formula 2(2)
where {tau} is the time constant of the response and {Delta}PmvFormula 2 is the difference between rest and steady-state contracting values.

When a marked biphasic PmvFormula 2 response occurred (i.e., PmvFormula 2 falling transiently to values below steady state) prior to the attainment of a steady state, a second exponential term was included in the model to reduce the residual sum of squares

Formula 3(3)
where A1 (primary response) and A2 (secondary response) are the amplitudes of the two components of the response, respectively, {tau}1 and {tau}2 are the time constants, and TD1 and TD2 are the independent time delays of the respective responses. The mean response time (MRT; estimates the time to 63% of primary exponential response) was calculated as TD1 + {tau}1 and provides an index of the rapidity of the PmvFormula 3 response after contraction onset.

For the normotensive condition, the single exponential with TD provided an excellent fit to the PmvFormula 3 data at the onset of contractions as judged from 1) coefficient of determination (r2), 2) sum of the squared residuals ({chi}2), and 3) visual inspection of the raw data and the fit of the residual error to a linear model (4). The single exponential did not provide a good fit to the PmvFormula 3 responses for the hypotensive condition; therefore, the more complex model with two exponentials (as described above), each with independent delays, was required to fit the PmvFormula 3 response (15). A fall in PmvFormula 3 below steady-state levels has been termed an "undershoot" (6, 15), and this was calculated as the difference between the minimum value for PmvFormula 3, which was typically at the nadir of the primary exponential fall in PmvFormula 3, and the subsequent PmvFormula 3 steady-state value. To determine whether the PmvFormula 3 undershoot was detectable statistically, we calculated the z-statistic to test the null hypothesis that the undershoot was not different from zero for the hypotensive condition (13). All model-dependent (e.g., {tau}, TD, MRT) and -independent (i.e., baseline, end-contracting PmvFormula 3) parameters and measurements, as well as blood flow and Formula 3O2m were analyzed with a one-way ANOVA. When appropriate, a Student-Newman-Keuls post hoc procedure was used to test for significance. In all instances, a significance level of P < 0.05 was accepted.


    RESULTS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Arteriosection of ~5 ml of blood (4.8 ± 0.3 ml) decreased MAP by ~39%, resulting in a significantly reduced MAP (normotensive, 97 ± 4 mmHg, hypotensive, 58 ± 3 mmHg; P < 0.05) in concert with a mild bradycardia after blood withdrawal (normotensive, 366 ± 1 beats/min, hypotensive, 318 ± 9 beats/min; P < 0.05). There were no changes in MAP throughout the contractions in either group. Hematocrit was significantly reduced (20 ± 4%) after the blood withdrawal, and arterial PO2 was elevated by 20 ± 3% (P < 0.05). Representative PmvFormula 3 responses to electrical stimulation and subsequent model fits for the spinotrapezius during normotensive and hypotensive conditions are illustrated in Fig. 1. As seen in Fig. 1 and presented below, the PmvFormula 3 at rest and the response profile across the rest-contractions transition differed substantially between normotensive and hypotensive conditions.


Figure 1
View larger version (15K):
[in this window]
[in a new window]
 
Fig. 1. Representative microvascular PO2 (PmvFormula 4) profiles in response to twitch contractions under normotensive and hypotensive conditions in the spinotrapezius muscle. Dashed line represents the model fit to the actual PmvFormula 4 data (solid line). Time zero is the onset of contractions. MAP, mean arterial pressure.

 
Muscle blood flow.   As illustrated in Table 1, during normotensive contracting, there was a threefold higher blood flow, consistent with this stimulation intensity (4, 7). As observed with animals used for PmvFormula 3 measurements, arteriosection resulted in a significant reduction in MAP as well as a mild bradycardia. Blood flow was reduced significantly with hypovolemic hypotension both at rest and during steady-state contractions (Table 1). In addition, muscle vascular conductance was reduced by ~63% in quiescent muscle during hypotension. Moreover, in the contracting spinotrapezius, there was a strong tendency (42%; P = 0.07) for lower vascular conductance during hypotension (Table 1).


View this table:
[in this window]
[in a new window]
 
Table 1. Resting and steady-state contracting spinotrapezius muscle hemodynamics and O2 uptake during normotension and hypotension (second set of rats)

 
Model-independent PmvFormula 3 data.   The precontracting, baseline PmvFormula 3 was significantly lower in the hypotensive condition (Fig. 2). Likewise, the steady-state contracting value was significantly lower in the hypotensive compared with the normotensive condition (8.7 ± 1.6 vs. 19.4 ± 2.4 Torr, respectively; P < 0.05). The change in PmvFormula 3 between baseline PmvFormula 3 and the steady-state of the PmvFormula 3 response, however, was not different between conditions (Fig. 2). In hypotension, but not normotension, PmvFormula 3 values fell transiently below end-contracting values, thus undershooting the steady state (Fig. 1). The value of this undershoot in the hypotensive condition (3.7 ± 0.6 Torr) was significantly different from zero.


Figure 2
View larger version (13K):
[in this window]
[in a new window]
 
Fig. 2. PmvFormula 4 data at rest (noncontracting baseline) and during the steady state of contractions under normotensive and hypotensive conditions. {Delta}, Baseline minus steady-state (SS) contracting values. Values are means ± SE; n = 7. *P < 0.05 vs. normotensive.

 
Model-dependent PmvFormula 3 data.   The single-exponential model provided an excellent fit to the PmvFormula 3 data for the normotensive condition. In contrast, six of the seven responses in the hypotensive condition required the more complex two-component model to fit the data adequately. This resulted from the presence of the pronounced undershoot (i.e., transient decrease to a PmvFormula 3 value below that present at the cessation of contractions) as noted above.

Hypovolemic hypotension resulted in a significant speeding of PmvFormula 3 dynamics parameters (Fig. 3). Specifically, TD1 was reduced on average 50% (~6 s) for the hypotensive condition, and {tau} was sped by ~40% (Fig. 3). This resulted in a significantly reduced MRT in the hypotensive vs. normotensive condition (13.2 ± 1.5 vs. 24.4 ± 1.9 s, respectively; P < 0.05; Figs. 3 and 4). In addition, the rate of PmvFormula 3 decline ({Delta}PmvFormula 3/{tau}) was doubled during the on transition in the hypotensive condition (2.2 ± 0.4 vs. 1.1 ± 0.1 Torr/s for hypotensive vs. normotensive, respectively; P < 0.05). In the hypotensive, but not normotensive, condition, there was a secondary rise in PmvFormula 3 that began 71 ± 17 s after the initiation of contractions (i.e., TD2). This secondary rise in PmvFormula 3 in the hypotensive condition increased with a time constant ({tau}2) of 82 ± 47 s, and thus the steady-state PmvFormula 3 was not approached until toward the end of the contractions bout.


Figure 3
View larger version (12K):
[in this window]
[in a new window]
 
Fig. 3. PmvFormula 4 dynamics under normotensive and hypotensive conditions. Time delay (TD) reflects the time from the onset of contractions to the point at which PmvFormula 4 exponential fall began (modeling data). Time constant ({tau}) represents the time taken to reach 63% of the primary exponential response after the TD. Mean response time (MRT) equals the time delay plus the time constant. Values are means ± SE; n = 7. *P < 0.05 vs. normotensive.

 

Figure 4
View larger version (10K):
[in this window]
[in a new window]
 
Fig. 4. Individual and average (±SE) MRT (TD + {tau}) of the primary component of the PmvFormula 4 response under normotensive (N) and hypotensive (H) conditions as a function of MAP.

 
Muscle O2 uptake.   During normotension, both resting and steady-state contracting Formula 3O2m were similar to those values calculated previously (5, 56). Specifically, the stimulation paradigm significantly increased muscle O2 uptake by ~4.5-fold (Table 1). Interestingly, induction of hypotension resulted in a substantial reduction in resting (~70%) and contracting (~64%) spinotrapezius Formula 3O2 (P < 0.05). At rest, extraction increased from 51% during normotension to 78% during hypotension. During the steady-state of contractions, extraction was ~78% during normotension and 94% during hypotension.


    DISCUSSION
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
This investigation has demonstrated that systemic hypovolemic hypotension dramatically alters the matching of Formula 3O2 to Formula 3O2 at rest and during contraction in skeletal muscle. Specifically, hypotension reduces vascular conductance both at rest and during the contracting steady state (Table 1). Moreover, O2 delivery was reduced to such a degree that the Formula 3O2 "reserve" (i.e., ability to increase fractional O2 extraction) was not adequate to prevent Formula 3O2 from falling. In addition, across the rest-contractions transition, hypotension accelerates the decline in PmvFormula 3, which falls to very low levels that are significantly below those observed in the normotensive state. PmvFormula 3 reflects directly the Formula 3O2-to-Formula 3O2 ratio (4, 5, 40); therefore, alterations in either Formula 3O2 or Formula 3O2 that impact the Formula 3O2-to-Formula 3O2 ratio will be reflected by changes in PmvFormula 3. Thus, consistent with a blunted Formula 3O2 across the rest-contractions transition, hypotension induced a transient reduction in PmvFormula 3 to below end-contracting (steady-state) values (Fig. 1). These low PmvFormula 3 values would be expected to slow the dynamics of muscle Formula 3O2. Specifically, Fig. 5 demonstrates the perturbations in Formula 3O2 and Formula 3O2 dynamics required to result in the observed PmvFormula 3 profile. Consequently, blunted Formula 3O2 dynamics would increase the O2 deficit, exacerbating the breakdown of phosphocreatine (25, 70). Lowered intramuscular phosphocreatine concentrations are associated with increased glycolysis and greater dependence on finite glycogen stores, which will reduce exercise tolerance. Because hypotension is one consequence of multiple physiological and pathological conditions, such as autonomic failure and cardiac diseases, these results (i.e., reduced PmvFormula 3 for transcapillary O2 flux) provide insight into the mechanism(s) of premature fatigue observed in these populations.


Figure 5
View larger version (18K):
[in this window]
[in a new window]
 
Fig. 5. Schematic modeling of 2 putative scenarios for the responses of muscle O2 utilization (Formula 4O2m; A) and O2 delivery (Formula 4O2; B) at contraction onset that can explain the observed effects of hypotension on PmvFormula 4(C) found in the present investigation. Left: Formula 4O2m kinetics held constant for normo- (N) and hypotensive (H) rats, which demonstrates the Formula 4O2 slowing that would have to be present to resolve the PmvFormula 4 kinetics observed herein. Right: more likely scenario in the face of the hypotension-induced reduction of PmvFormula 4 is that Formula 4O2m kinetics will be slowed and hence Formula 4O2 slowing must be exacerbated beyond that seen at left. Values for Formula 4O2m {tau} are from Behnke et al. (5). %S-S, percentage of the steady-state contracting value (noncontracting Formula 4O2m and Formula 4O2 set to 0% for clarity).

 
Hypotension and oxygen delivery.   With exercise in healthy normotensive individuals, there exists the potential for developing systemic hypotension due to the enormous capacity of skeletal muscle to augment vascular conductance (11, 16, 51). However, several mechanisms act in concert to divert flow from inactive regions (e.g., viscera) centrally for the purpose of maintaining or increasing MAP (16). Additionally, within muscle, there is a powerful sympathetic vasoconstrictor response that prevents excessive vasodilation of active or quiescent skeletal muscle (16). In this manner, MAP is defended and Formula 3 to essential organs such as the brain, which has a very low tolerance to blood flow deprivation, is sustained (for review, see Ref. 16). Local skeletal muscle perfusion is also regulated in proportion to tissue metabolism (Formula 3O2; reviewed in Ref. 34), i.e., metabolic regulation of Formula 3 such that O2 delivery in the steady state increases proportionally with Formula 3O2 demands. Indeed, under normal conditions at the onset of exercise, when muscle Formula 3O2 increases without discernible delay (i.e., <2 s) (5), there is a rapid increase in O2 delivery that matches or exceeds the increase in muscle Formula 3O2 (3, 4, 19) such that PmvFormula 3 does not fall below baseline values (reflecting a decreased or constant arterial-to-venous O2 difference) for 10–20 s after the onset of contractions. This response maximizes the O2 driving pressure to facilitate blood-muscle O2 diffusion.

In hypovolemic hypotension, the body attempts to restore MAP by evoking a complex array of responses that includes augmented sympathetic activity (30), which induces a profound arteriolar and to a lesser extent a venular vasoconstriction (8), evidenced herein by a reduced resting Formula 3 (Table 1). Enhanced sympathetic activation has been shown to blunt the early increase in Formula 3O2 (first 15–20 s; phase 1) after the onset of contractions (65). This would markedly speed the PmvFormula 3 kinetics and create an "undershoot" of the response (18). MAP remains relatively constant throughout the transition to exercise in healthy normotensive individuals (61, 65), and our results support the notion that maintenance of an adequate upstream pressure, i.e., MAP, is critical to the Formula 3O2 response. The early rapid increase in Formula 3O2 appears to be largely dependent on the increased {Delta}P due to the muscle pump effect (34), such that Formula 3O2 increases at a faster rate than muscle Formula 3O2 (normotension) (5), whereas the subsequent phase of Formula 3O2 depends on vasodilation and maintenance of {Delta}P. Therefore, hypotension will further impair the initial increase in Formula 3O2 (due to decreased {Delta}P) as well as blunt the Formula 3O2 response after 15–20 s (phase 2), as vasodilation must presumably overcome an enhanced neurally mediated vasoconstriction. The PmvFormula 3 kinetics observed in our study during hypotension (rapid undershoot and subsequent slow increase to steady state) are consequent to a concomitant decrease in {Delta}P and vascular conductance (Table 1) that affects both phases of the Formula 3O2 response such that Formula 3O2 increases less compared with normotension and at a slower rate than muscle Formula 3O2 (Fig. 5). There is also evidence that low Formula 3 conditions induce a red blood cell aggregation in venous vessels, and this may contribute to increased vascular resistance and further limit increases in Formula 3 with hypotension (10). Consistent with this notion, the biphasic PmvFormula 3 response (Fig. 1) present during hypotension is similar to that observed in skeletal muscle of rats with Type 1 diabetes (6) and also CHF (15), which shows very slow Formula 3 and Formula 3O2 dynamics (53).

Conditions in which hypotension and slowed muscle Formula 3O2 could contribute directly to exercise intolerance include autonomic failure (58) and chronic fatigue syndrome. Individuals with chronic fatigue syndrome exhibit an impaired central (62) and muscle hemodynamic response to exercise (39), which mandates a greater breakdown of high-energy phosphates (see below). Moreover, as mentioned in the introduction, systemic hypotension and exercise intolerance are observed in several pathological conditions, including mitral valve prolapse (9, 28), CHF (38), and idiopathic chronic fatigue (37). In these conditions (i.e., systemic hypotension), when the individual attempts to exercise, there may be insufficient Formula 3O2 across the rest-exercise transition to preserve the PmvFormula 3 pressure head necessary to drive oxidative metabolism, which, once again, will necessitate incurring a larger O2 deficit and its associated intracellular consequences, possibly resulting in a reduced Formula 3O2.

Oxygen uptake and hypotension.   Because PmvFormula 3 reflects the dynamic balance between Formula 3O2 and Formula 3O2, the argument could be posited that the lower precontracting and steady-state values in hypotension (Fig. 2) are the result of an increased Formula 3O2 rather than a lower Formula 3O2. However, as observed in Table 1, a reduced rather than increased Formula 3O2 was observed. There exists only a finite capacity to maintain Formula 3O2 in the face of falling O2 delivery, i.e., fractional O2 extraction can only increase to ≤100%. In the present investigation, O2 delivery during hypotension was reduced to such a degree that the ability to maintain Formula 3O2 was compromised (Table 1). Thus the contribution of ATP supplied via oxidative metabolism would be substantially reduced; therefore, reliance on alternative energy sources (e.g., anaerobic glycogenolysis) would be increased. Although not measured herein (see Experimental considerations below), fatigue would likely occur much more rapidly with a reduced Formula 3O2 in the hypotension condition, since we would not expect muscle ATP requirements during contractions per se to be altered with hypotension.

The functional significance of a reduced O2 availability (i.e., reduced PmvFormula 3) would be slowed Formula 3O2 kinetics (17, 26, 35) and, if of great enough magnitude, reduced steady-state Formula 3O2, although the ATP requirement for contractions would not be expected to change. However, the slowed Formula 3O2 kinetics would mandate a greater reliance on immediate (i.e., PCr breakdown) and anaerobic energy sources (i.e., glycogenolysis) to maintain energy output by the working muscle (70). This notion can be conceptualized by consideration of the overall equation for oxidative metabolism (24):

Formula 4(4)
At a given ATP (thus Formula 4O2) demand, O2 availability (or pressure) at the mitochondria can modulate the concentrations of the other substrates (25, 69, 70). Kindig et al. (31) have demonstrated in single Xenopus laevis muscle fibers that intracellular PO2 falls more rapidly and to lower levels with a reduction in extracellular PO2 (broadly synonymous to decreased PmvFormula 4). Thus the hypotensive state in the present investigation resulted in a lowered PmvFormula 4, thereby reducing intracellular PO2; consequently, muscle ATP turnover could be maintained only at the expense of lowered intracellular energy levels (i.e., reduced [ATP]/[ADP][Pi], [NAD+]/[NADH], and [PCr], where brackets denote concentration) (see Eq. 4; Refs. 24, 70). Consistent with this notion, across the rest-to-exercise transient, skeletal muscle [PCr] does appear to fall more and end-exercise [ATP] is lowered in patients with CFS-induced hypotension (71). Because these patients do not exhibit either differences in muscle fiber characteristics (32) or abnormalities in resting glycolysis or oxidative metabolism (33), the greater decline in [PCr] and the lower end-exercise intracellular pH (33) can both be explained by the presence of a lower MAP and muscle vascular conductance and therefore an imbalance between Formula 4O2 and Formula 4O2 requirements early during the exercise bout such that PmvFormula 4 falls below those levels present in healthy individuals.

Recently, Haseler et al. (21) reported that reducing arterial O2 pressures [PaO2, via lowering the inspired fraction of O2 (FIO2)] does not alter initial PCr on kinetics to submaximal exercise in human gastrocnemius muscle vs. normoxia. However, with a reduced FIO2, there is an overall greater percent decrease in PCr (20, 52), suggesting a greater change in phosphorylation potential (i.e., [PCr/Pi]) to maintain a given cellular respiration rate (68, 69). In those studies, although there was a reduced PaO2, the ability for a compensatory increase in blood flow to buffer the reduced O2 content of arterial blood was not compromised (i.e., no large changes in MAP). However, in the present study where arterial O2 content was slightly decreased (due to reduced hematocrit), the ability to augment muscle blood flow, and therefore increase O2 delivery, was greatly diminished. Indeed, with a reduced PmvFormula 4(Fig. 1), cellular respiration rates were affected such that muscle O2 uptake at rest and during contractions was reduced significantly vs. that during normoxia (Table 1).

Experimental considerations.   We chose to reduce MAP to ~60 mmHg because 1) it has been demonstrated that this level of hypotension results in a large redistribution of blood flow, which maintains cerebral circulation (55), 2) there is no speeding of PmvFormula 4 kinetics at the onset of contractions with MAP above 70 mmHg (stimulation parameters identical to those used herein; Behnke and Poole, unpublished observations), and 3) autoregulatory corrections in cerebral vascular resistance fail when MAP falls below 50 mmHg (64). The latter consideration would not affect the results of the present investigation because none of the animals had MAP values below ~55 mmHg during hypotension.

Interestingly, in the present investigation, hypovolemic hypotension induced a modest bradycardia. This appears to contradict the expected baroreflex-mediated tachycardia; however, the bradycardia observed in the present study is not an unusual accompaniment to severe hemorrhage (44). This apparently paradoxical response results from activation of left ventricular C fibers (43).

Attachment of a force transducer to the intact spinotrapezius (in the in situ position) compromises the functional integrity of the muscle (alters muscle Formula 4). In the present investigation, measurement of muscle fatigue would have been desirable. However, it is a reasonable supposition that in the hypovolemic condition, with a reduced ATP contribution via oxidative phosphorylation (Table 1) and an unchanged external ATP demand (stimulation parameters held constant), anaerobic and immediate energy reserves would be depleted more rapidly and the onset of fatigue accelerated.

In conclusion, both syncope and presyncope are found within the otherwise healthy population and hypotension is a common adjunct to multiple clinical conditions. The present investigation has determined that, during hypovolemic hypotension, a reduced microvascular PO2 (PmvFormula 4) is present within muscle at rest, across the transition to contractions, and in the subsequent steady state. These findings suggest that exercise intolerance and muscle dysfunction during hypotension can result from O2 exchange impairments resulting from an impaired diffusive O2 delivery and also a lowered intracellular PO2 consequent to this reduced PmvFormula 4.


    GRANTS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
This work was supported by National Institutes of Health Grants HLBI-50306, HL-69739 (to D. J. Padilla), HL-71270 (to B. J. Behnke), and AG-12298 (to T. I. Musch), National Aeronautics and Space Administration NNA04CC66G (M. D. Delp), and a Grant-in-Aid from the American Heart Association, Heartland Affiliate (D. C. Poole).


    FOOTNOTES
 

Address for reprint requests and other correspondence: D. C. Poole, Dept. Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66505-5802 (e-mail: poole{at}vet.ksu.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


    REFERENCES
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Aronow WS. Atrial fibrillation. Heart Dis 4: 91–101, 2002.[CrossRef][Medline]
  2. Bailey JK, Kindig CA, Behnke BJ, Musch TI, Schmid-Schoenbein GW, and Poole DC. Spinotrapezius muscle microcirculatory function: effects of surgical exteriorization. Am J Physiol Heart Circ Physiol 279: H3131–H3137, 2000.[Abstract/Free Full Text]
  3. Bangsbo J, Krustrup P, Gonzalez-Alonso J, Boushel R, and Saltin B. Muscle oxygen kinetics at onset of intense dynamic exercise in humans. Am J Physiol Regul Integr Comp Physiol 279: R899–R906, 2000.[Abstract/Free Full Text]
  4. Behnke BJ, Kindig CA, Musch TI, Koga S, and Poole DC. Dynamics of microvascular oxygen pressure across the rest-exercise transition in rat skeletal muscle. Respir Physiol 126: 53–63, 2001.[CrossRef][Web of Science][Medline]
  5. Behnke BJ, Barstow TJ, Kindig CA, McDonough P, Musch TI, and Poole DC. Dynamics of oxygen uptake following exercise onset in rat skeletal muscle. Respir Physiol Neurobiol 133: 229–239, 2002.[CrossRef][Web of Science][Medline]
  6. Behnke BJ, Kindig CA, McDonough P, Poole DC, and Sexton WL. Dynamics of microvascular oxygen pressure during rest-contraction transition in skeletal muscle of diabetic rats. Am J Physiol Heart Circ Physiol 283: H926–H932, 2002.[Abstract/Free Full Text]
  7. Behnke BJ, Kindig CA, Musch TI, Sexton WL, and Poole DC. Effects of prior contractions on muscle microvascular oxygen pressure at onset of subsequent contractions. J Physiol 539: 927–934, 2002.[Abstract/Free Full Text]
  8. Bishop JJ, Nance PR, Popel AS, Intaglietta M, and Johnson PC. Diameter changes in skeletal muscle venules during arterial pressure reduction. Am J Physiol Heart Circ Physiol 279: H47–H57, 2000.[Abstract/Free Full Text]
  9. Boudoulas H and Wooley CF. Mitral valve prolapse syndrome: neuro-endocrinological aspects. Herz 13: 249–258, 1988.[Web of Science][Medline]
  10. Cabel M, Meiselman HJ, Popel AS, and Johnson PC. Contribution of red blood cell aggregation to venous vascular resistance in skeletal muscle. Am J Physiol Heart Circ Physiol 272: H1020–H1032, 1997.[Abstract/Free Full Text]
  11. Calbet JA, Jensen-Urstad M, van Hall G, Holmberg HC, Rosdahl H, and Saltin B. Maximal muscular vascular conductances during whole body upright exercise in humans. J Physiol 558: 319–331, 2005.
  12. Charkoudian N, Halliwill JR, Morgan BJ, Eisenach JH, and Joyner MJ. Influences of hydration on post-exercise cardiovascular control in humans. J Physiol 552: 635–644, 2003.[Abstract/Free Full Text]
  13. Colton T. Statistics in Medicine. Boston: Little, Brown, 1974, p. 113.
  14. Convertino VA. Mechanisms of microgravity induced orthostatic intolerance: implications for effective countermeasures. J Gravit Physiol 9: 1–13, 2002.[Medline]
  15. Diederich ER, Behnke BJ, McDonough P, Kindig CA, Barstow TJ, Poole DC, and Musch TI. Dynamics of microvascular oxygen partial pressure in contracting skeletal muscle of rats with chronic heart failure. Cardiovasc Res 56: 479–486, 2002.[Abstract/Free Full Text]
  16. Delp MD and O'Leary DS. Integrative control of the skeletal muscle microcirculation in the maintenance of arterial pressure during exercise. J Appl Physiol 97: 1112–1118, 2004.[Abstract/Free Full Text]
  17. Engelen M, Porszasz J, Riley M, Wasserman K, Maehara K, and Barstow TJ. Effects of hypoxic hypoxia on O2 uptake and heart rate kinetics during heavy exercise. J Appl Physiol 81: 2500–2508, 1996.[Abstract/Free Full Text]
  18. Ferreira LF, Poole DC, and Barstow TJ. Muscle blood flow-O2 uptake interaction and their relation to on-exercise dynamics of O2 exchange. Respir Physiol Neurobiol 147: 91–103, 2005.[CrossRef][Web of Science][Medline]
  19. Grassi B, Poole DC, Richardson RS, Knight DR, Erickson BK, and Wagner PD. Muscle O2 uptake kinetics in humans: implications for metabolic control. J Appl Physiol 80: 988–998, 1996.[Abstract/Free Full Text]
  20. Haseler LJ, Richardson RS, Videem JS, and Hogan MC. Phosphocreatine hydrolysis during submaximal exercise: the effect of FIO2. J Appl Physiol 85: 1457–1463, 1998.[Abstract/Free Full Text]
  21. Haseler LJ, Kindig CA, Richardson RS, and Hogan MC. The role of oxygen in determining phosphocreatine onset kinetics in exercising humans. J Physiol 558: 985–992, 2004.[Abstract/Free Full Text]
  22. Hasser EM and Moffitt JA. Regulation of sympathetic nervous system function after cardiovascular deconditioning. Ann NY Acad Sci 940: 454–468, 2001.[Web of Science][Medline]
  23. Hepple RT, Liu PP, Plyley MJ, and Goodman JM. Oxygen uptake kinetics during exercise in chronic heart failure: influence of peripheral vascular reserve. Clin Sci (Lond) 97: 569–577, 1999.[Medline]
  24. Hinkle PC. P/O ratios of mitochondrial oxidative phosphorylation. Biochim Biophys Acta 1706: 1–11, 2005.[Medline]
  25. Hogan MC, Arthur PG, Bebout DE, Hochachka PW, and Wagner PD. Role of O2 in regulating tissue respiration in dog muscle working in situ. J Appl Physiol 73: 728–736, 1992.[Abstract/Free Full Text]
  26. Hughson RL and Kowalchuk JM. Kinetics of oxygen uptake for submaximal exercise in hyperoxia, normoxia, and hypoxia. Can J Appl Physiol 20: 198–210, 1995.[Web of Science][Medline]
  27. Ishise S, Pegram BL, Yamamoto J, Kitamura Y, and Frolich ED. Reference sample microsphere method: cardia output and blood flows in conscious rat. Am J Physiol Heart Circ Physiol 238: H433–H449, 1980.
  28. Iskandrian AS. Exercise left ventricular performance in patients with mitral valve prolapse. Herz 13: 243–248, 1988.[Web of Science][Medline]
  29. Karas B, Grubb BP, Boehm K, and Kip K. The postural orthostatic tachycardia syndrome: a potentially treatable cause of chronic fatigue, exercise intolerance, and cognitive impairment in adolescents. Pacing Clin Electrophysiol 23: 344–351, 2000.[CrossRef][Medline]
  30. Kimmerly DS and Shoemaker JK. Hypovolemia and neurovascular control during orthostatic stress. Am J Physiol Heart Circ Physiol 282: H645–H655, 2002.[Abstract/Free Full Text]
  31. Kindig CA, Howlett RA, and Hogan MC. Effect of extracellular PO2 on the fall in intracellular PO2 in contracting single myocytes. J Appl Physiol 94: 1964–1970, 2003.[Abstract/Free Full Text]
  32. Lane RJ, Barrett MC, Woodrow D, Moss J, Fletcher R, and Archard LC. Muscle fibre characteristics and lactate responses to exercise in chronic fatigue syndrome. J Neurol Neurosurg Psychiatry 64: 362–367, 1998.[Abstract/Free Full Text]
  33. Lane RJ, Barrett MC, Taylor DJ, Kemp GJ, and Lodi R. Heterogeneity in chronic fatigue syndrome: evidence from magnetic resonance spectroscopy of muscle. Neuromuscul Disord 8: 204–209, 1998.[CrossRef][Web of Science][Medline]
  34. Laughlin MH, Korthuis RJ, Dunker DJ, and Bache RJ. Control of blood flow to cardiac and skeletal muscle during exercise. In: Handbook of Physiology. Exercise, Regulation, and Integration of Multiple Systems. Bethesda, MD: Am. Physiol. Soc., 1996, sect. 12, chapt. 16, p. 705–769.
  35. Linnarsson D, Karlsson J, Fagraeus L, and Saltin B. Muscle metabolites and oxygen deficit with exercise in hypoxia and hyperoxia. J Appl Physiol 36: 399–402, 1974.[Free Full Text]
  36. Lo LW, Vinogradov SA, Koch CJ, and Wilson DF. A new, water soluble, phosphor for oxygen measurements in vivo. Adv Exp Med Biol 428: 651–656, 1997.[Web of Science][Medline]
  37. Lucas KE, Rowe PC, Coresh J, Klag MJ, Meoni LA, and Ford DE. Prospective association between hypotension and idiopathic chronic fatigue. J Hypertens 22: 691–695, 2004.[CrossRef][Web of Science][Medline]
  38. Mabee SW, Metra M, Reed DE, Dei Cas L, and Cody RJ. Pulmonary hypertension and systemic hypotension as limitations to exercise in chronic heart failure. J Card Fail 1: 27–33, 1994.[CrossRef][Medline]
  39. McCully KK, Smith S, Rajaei S, Leigh JS Jr, and Natelson BH. Muscle metabolism with blood flow restriction in chronic fatigue syndrome. J Appl Physiol 96: 871–878, 2004.[Abstract/Free Full Text]
  40. McDonough P, Behnke BJ, Kindig CA, and Poole DC. Rat muscle microvascular PO2 kinetics during the exercise off-transient. Exp Physiol 86: 349–356, 2001.[Abstract]
  41. Mtinangi BL and Hainsworth R. Increased orthostatic tolerance following moderate exercise training in patients with unexplained syncope. Heart 80: 596–600, 1998.[Abstract/Free Full Text]
  42. Musch TI and Terrell JA. Skeletal muscle blood flow abnormalities in rats with chronic myocardial infarction: rest and exercise. Am J Physiol Heart Circ Physiol 262: H411–H419, 1992.[Abstract/Free Full Text]
  43. Oberg B and Thoren P. Increased activity in left ventricular receptors during hemorrhage or occlusion of caval veins in the cat: a possible cause of the vaso-vagal reaction. Acta Physiol Scand 85: 164–173, 1972.[Web of Science][Medline]
  44. Oberg B and White S. The role of vagal cardiac nerves and arterial baroreceptors in the circulatory adjustments to hemorrhage in the cat. Acta Physiol Scand 80: 395–403, 1970.[Medline]
  45. Packer M, Lee WH, Medina N, and Yushak M. Hemodynamic and clinical significance of the pulmonary vascular response to long-term captopril therapy in patients with severe chronic heart failure. J Am Coll Cardiol 6: 635–645, 1985.[Abstract]
  46. Pawlowski M and Wilson DF. Monitoring of the oxygen pressure in the blood of live animals using the oxygen dependent quenching of phosphorescence. Adv Exp Med Biol 316: 179–185, 1992.[Medline]
  47. Poole DC, Behnke BJ, McDonough P, McAllister RM, and Wilson DF. Measurement of muscle microvascular oxygen pressures: compartmentalization of phosphorescent probe. Microcirculation 11: 317–326, 2004.[CrossRef][Web of Science][Medline]
  48. Razumovsky AY, DeBusk K, Calkins H, Snader S, Lucas KE, Vyas P, Hanley DF, and Rowe PC. Cerebral and systemic hemodynamics changes during upright tilt in chronic fatigue syndrome. J Neuroimaging 13: 57–67, 2003.[CrossRef][Medline]
  49. Regensteiner JG, Bauer TA, Reusch JE, Brandenburg SL, Sippel JM, Vogelsong AM, Smith S, Wolfel EE, Eckel RH, and Hiatt WR. Abnormal oxygen uptake kinetic responses in women with type II diabetes mellitus. J Appl Physiol 85: 310–317, 1998.[Abstract/Free Full Text]
  50. Renkin EM and Tucker VL. Measurement of microvascular transport parameters of macromolecules in tissues and organs of intact animals. Microcirculation 5: 139–152, 1998.[CrossRef][Web of Science][Medline]
  51. Richardson RS, Knight DR, Poole DC, Kurdak SS, Hogan MC, Grassi B, and Wagner PD. Determinants of maximal exercise Formula 4O2 during single leg knee-extensor exercise in humans. Am J Physiol Heart Circ Physiol 268: H1453–H1461, 1995.[Abstract/Free Full Text]
  52. Richardson RS, Leigh JS, Wagner PD, and Noyszewski EA. Cellular PO2 as a determinant of maximal mitochondrial O2 consumption in trained human skeletal muscle. J Appl Physiol 87: 325–331, 1999.[Abstract/Free Full Text]
  53. Richardson TE, Kindig CA, Musch TI, and Poole DC. Effects of chronic heart failure on skeletal muscle capillary hemodynamics at rest and during contractions. J Appl Physiol 95: 1055–1062, 2003.[Abstract/Free Full Text]
  54. Roca J, Agusti AG, Alonso A, Poole DC, Viegas C, Barbera JA, Rodriguez-Roisin R, Ferrer A, and Wagner PD. Effects of training on muscle O2 transport at Formula 4O2 max. J Appl Physiol 73: 1067–1076, 1992.[Abstract/Free Full Text]
  55. Rosberg B and Wulff K. Regional blood flow in normovolaemic and hypovolaemic haemodilution. An experimental study. Br J Anaesth 51: 423–430, 1979.[Abstract/Free Full Text]
  56. Russell JA, Kindig CA, Behnke BJ, Poole DC, and Musch TI. Effects of aging on capillary geometry and hemodynamics in rat spinotrapezius muscle. Am J Physiol Heart Circ Physiol 285: H251–H258, 2003.[Abstract/Free Full Text]
  57. Rumsey WL, Vanderkooi JM, and Wilson DF. Imaging of phosphorescence: a novel method for measuring oxygen distribution in perfused tissue. Science 241: 1649–1651, 1988.[Abstract/Free Full Text]
  58. Schrage WG, Eisenach JH, Dinenno FA, Roberts SK, Johnson CP, Sandroni P, Low PA, and Joyner MJ. Effects of midodrine on exercise-induced hypotension and blood pressure recovery in autonomic failure. J Appl Physiol 97: 1978–1984, 2004.[Abstract/Free Full Text]
  59. Sheriff DD, Zhou XP, Scher AM, and Rowell LB. Dependence of cardiac filling pressure on cardiac output during rest and dynamic exercise in dogs. Am J Physiol Heart Circ Physiol 265: H316–H322, 1993.[Abstract/Free Full Text]
  60. Shiraishi Y, Mochizuki T, and Ikeda K. Oxygen uptake and carbon dioxide elimination during controlled hypotension induced by prostaglandin E1 or nitroglycerin. Br J Anaesth 72: 439–442, 1994.[Abstract/Free Full Text]
  61. Sietsema KE, Ben-Dov I, Zhang YY, Sullivan C, and Wasserman K. Dynamics of oxygen uptake for submaximal exercise and recovery in patients with chronic heart failure. Chest 105: 1693–1700, 1994.[CrossRef][Web of Science][Medline]
  62. Soetekouw PM, Lenders JW, Bleijenberg G, Thien T, and van der Meer JW. Autonomic function in patients with chronic fatigue syndrome. Clin Auton Res 9: 334–340, 1999.[CrossRef][Web of Science][Medline]
  63. Tang S, Calkins H, and Petri M. Neurally mediated hypotension in systemic lupus erythematosus patients with fibromyalgia. Rheumatology (Oxford) 43: 609–614, 2004.[Medline]
  64. Toyoda K, Fujii K, Ibayashi S, Sadoshima S, and Fujishima M. Changes in arterioles, arteries, and local perfusion of the brain during hemorrhagic hypotension. Am J Physiol Heart Circ Physiol 270: H1350–H1354, 1996.[Abstract/Free Full Text]
  65. Tschakovsky ME and Hughson RL. Rapid blunting of sympathetic vasoconstriction in the human forearm at the onset of exercise. J Appl Physiol 94: 1785–1792, 2003.[Abstract/Free Full Text]
  66. Vinogradov SA, Fernandez-Searra MA, Dugan BW, and Wilson DF. Frequency domain instrument for measuring phosphorescence lifetime distributions in heterogeneous samples. Rev Sci Instrum 72: 3396–3406, 2001.[CrossRef][Web of Science]
  67. Vinogradov SA and Wilson DF. Phosphorescence lifetime analysis with a quadratic programming algorithm for determining quencher distributions in heterogeneous systems. Biophys J 67: 2048–2059, 1994.[Web of Science][Medline]
  68. Wilson DF and Rumsey WL. Factors modulating the oxygen dependence of mitochondrial oxidative phosphorylation. Adv Exp Med Biol 222: 121–131, 1988.[Medline]
  69. Wilson DF, Erecinska M, Drown C, and Silver IA. The oxygen dependence of cellular energy metabolism. Arch Biochem Biophys 195: 485–493, 1979.[CrossRef][Web of Science][Medline]
  70. Wilson DF, Owen CS, and Holian A. Control of mitochondrial respiration: a quantitative evaluation of the roles of cytochrome c and oxygen. Arch Biochem Biophys 182: 749–762, 1977.[CrossRef][Web of Science][Medline]
  71. Wong R, Lopaschuk G, Zhu G, Walker D, Catellier D, Burton D, Teo K, Collins-Nakai R, and Montague T. Skeletal muscle metabolism in the chronic fatigue syndrome. In vivo assessment by 31P nuclear magnetic resonance spectroscopy. Chest 102: 1716–1722, 1992.[Medline]
  72. Ziegler D. Diagnosis and treatment of diabetic autonomic neuropathy. Curr Diab Rep 1: 216–227, 2001.[Medline]



This article has been cited by other articles:


Home page
J. Appl. Physiol.Home page
R. C. Davies, R. G. Eston, D. C. Poole, A. V. Rowlands, F. DiMenna, D. P. Wilkerson, C. Twist, and A. M. Jones
Effect of eccentric exercise-induced muscle damage on the dynamics of muscle oxygenation and pulmonary oxygen uptake
J Appl Physiol, November 1, 2008; 105(5): 1413 - 1421.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
B. J. Behnke, M. D. Delp, D. C. Poole, and T. I. Musch
Aging potentiates the effect of congestive heart failure on muscle microvascular oxygenation
J Appl Physiol, November 1, 2007; 103(5): 1757 - 1763.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
N. Lai, G. M. Saidel, B. Grassi, L. B. Gladden, and M. E. Cabrera
Model of oxygen transport and metabolism predicts effect of hyperoxia on canine muscle oxygen uptake dynamics
J Appl Physiol, October 1, 2007; 103(4): 1366 - 1378.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
100/3/1019    most recent
00388.2005v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Behnke, B. J.
Right arrow Articles by Poole, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Behnke, B. J.
Right arrow Articles by Poole, D. C.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.